Article Text

Download PDFPDF
Letter response
Response to: ‘Impact of gender on outcomes in ankylosing spondylitis’ by Feldtkeller et al
  1. Irene van der Horst-Bruinsma1,
  2. Debra Zack2,
  3. Annette Szumski3,
  4. Andrew S Koenig3
  1. 1Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands
  2. 2Department of Global Development, Amgen Inc., Thousand Oaks, California, USA
  3. 3Department of Inflammation & Immunology, Pfizer Inc., Collegeville, Pennsylvania, USA
  1. Correspondence to Dr I E van der Horst-Bruinsma, Department of Rheumatology, VU University Medical Centre, 3A-47, PO Box 7057, 1007 MB Amsterdam, The Netherlands; Email: IE.vanderHorst{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We would like to thank Dr Feldtkeller1 for his remarks regarding our manuscript.1 We do agree that in ankylosing spondylitis onset is more accurately described by onset of symptoms as opposed to age at diagnosis. Unfortunately, we did not collect the time-of-symptom-onset data in three of the four studies in this analysis. Thus, we used the age at diagnosis as proxy for disease onset. In the ASCEND study (women n=147; men n=419) we reviewed the onset of symptom data that was similar between women (mean 13.0 years) and men (mean 13.4 years), which supports Dr Feldtkeller's statement, “the average age of disease onset (first symptoms of AS) does not differ significantly between male and female patients with AS”.24 In addition, the mean age of diagnosis in the …

View Full Text


  • Funding Editorial support was provided by Stephanie Eide of Engage Scientific Solutions and was funded by Pfizer Inc.

  • Competing interests IvdH-B is an investigator for clinical trials sponsored by Pfizer Inc. DZ is a former employee of Amgen. AS is an employee of Inventiv Health Inc who is a paid contractor to Pfizer Inc. AK is an employee of Pfizer.

  • Patient consent Obtained.

  • Ethics approval IRB (local sites for global study).

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles